HomeCompareGSGTF vs EPRT

GSGTF vs EPRT: Dividend Comparison 2026

GSGTF yields 1052.08% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GSGTF wins by $29376466.49M in total portfolio value
10 years
GSGTF
GSGTF
● Live price
1052.08%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29376466.55M
Annual income
$24,748,961,707,406.69
Full GSGTF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GSGTF vs EPRT

📍 GSGTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGSGTFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GSGTF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GSGTF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GSGTF
Annual income on $10K today (after 15% tax)
$89,426.62/yr
After 10yr DRIP, annual income (after tax)
$21,036,617,451,295.69/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, GSGTF beats the other by $21,036,617,440,381.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GSGTF + EPRT for your $10,000?

GSGTF: 50%EPRT: 50%
100% EPRT50/50100% GSGTF
Portfolio after 10yr
$14688233.31M
Annual income
$12,374,480,860,123.71/yr
Blended yield
84.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GSGTF
No analyst data
Altman Z
-9.7
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GSGTF buys
0
EPRT buys
0
No recent congressional trades found for GSGTF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGSGTFEPRT
Forward yield1052.08%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$29376466.55M$63.4K
Annual income after 10y$24,748,961,707,406.69$12,840.73
Total dividends collected$29025351.72M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: GSGTF vs EPRT ($10,000, DRIP)

YearGSGTF PortfolioGSGTF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$115,908$105,207.79$11,205$505.18+$104.7KGSGTF
2$1,263,685$1,139,663.68$12,672$682.46+$1.25MGSGTF
3$12,964,467$11,612,324.37$14,490$930.48+$12.95MGSGTF
4$125,211,982$111,340,001.64$16,786$1,282.69+$125.20MGSGTF
5$1,138,959,685$1,004,982,865.01$19,753$1,791.56+$1138.94MGSGTF
6$9,762,216,739$8,543,529,875.74$23,677$2,541.64+$9762.19MGSGTF
7$78,882,996,544$68,437,424,632.64$29,008$3,672.99+$78882.97MGSGTF
8$601,231,379,017$516,826,572,714.96$36,463$5,425.08+$601231.34MGSGTF
9$4,324,770,879,470$3,681,453,303,922.24$47,238$8,221.57+$4324770.83MGSGTF
10$29,376,466,548,439$24,748,961,707,406.69$63,385$12,840.73+$29376466.49MGSGTF

GSGTF vs EPRT: Complete Analysis 2026

GSGTFStock

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Full GSGTF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GSGTF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GSGTF vs SCHDGSGTF vs JEPIGSGTF vs OGSGTF vs KOGSGTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.